Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
| Autor: | Anna Jamnitski, Michael T. Nurmohamed, B A C Dijkmans, A E Voskuyl, M. Hart, L. A. Aarden, C. Krieckaert, G.J. Wolbink |
|---|---|
| Přispěvatelé: | Rheumatology, ICaR - Circulation and metabolism, CCA - Innovative therapy |
| Rok vydání: | 2011 |
| Předmět: |
musculoskeletal diseases
Adult Male medicine.medical_specialty Immunology Arthritis Severity of Illness Index General Biochemistry Genetics and Molecular Biology Receptors Tumor Necrosis Factor Etanercept Arthritis Rheumatoid Rheumatology Internal medicine Severity of illness medicine Immunology and Allergy Humans Dosing Treatment Failure skin and connective tissue diseases Aged medicine.diagnostic_test business.industry Tumor Necrosis Factor-alpha Middle Aged medicine.disease Clinical trial Therapeutic drug monitoring Rheumatoid arthritis Antirheumatic Agents Immunoglobulin G Female Drug Monitoring business Rheumatism medicine.drug Follow-Up Studies |
| Zdroj: | Annals of the Rheumatic Diseases, 71(1), 88-91. BMJ Publishing Group Jamnitski, A, Krieckaert, C L, Nurmohamed, M T, Hart, M H, Dijkmans, B A C, Aarden, L, Voskuyl, A E & Wolbink, G J 2012, ' Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients ', Annals of the Rheumatic Diseases, vol. 71, no. 1, pp. 88-91 . https://doi.org/10.1136/annrheumdis-2011-200184 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2011-200184 |
| Popis: | ObjectiveTo investigate the relationship between serum etanercept levels and clinical response.MethodsIn 292 etanercept-treated patients with rheumatoid arthritis clinical and pharmacological data were determined at baseline and after 1, 4 and 6 months of etanercept treatment. Differences in etanercept levels between good, moderate and European League Against Rheumatism (EULAR) non-responders were assessed after 6 months of therapy.ResultsAfter 6 months of therapy etanercept levels were significantly higher in good responders (median (IQR) 3.78 (2.53–5.17)) compared with both moderate 3.10 (2.12–4.47) and EULAR non-responders 2.80 (1.27–3.93) (all p4.7 mg/l) comprised 35% of all good EULAR responders. Anti-etanercept antibodies were detected in none of the sera.ConclusionThe authors demonstrated that lower etanercept levels were associated with non-response. Therapeutic drug monitoring and the possibility of the adjusted dosing regimes in the selected groups of patients should be investigated further as a possible tool to optimise treatment with etanercept. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|